Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06692426 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Cell Based Therapy for DMD

StatusRecruiting
PhasePhase 1
Started2025-03-20
View on ClinicalTrials.gov ↗

Amendment history

2026-03-02
Study Status, Study Description v4
Study description-133 characters
[...] nesota in accordance with its conflict of interest policies. If you would like further information please contact Jon Guden, Associate Director, Conflict of Interest Program, at jguden@umn.edu.
2025-03-21
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-05-16→confirmed 2025-03-20
Study sites0→1
2025-01-24
Study Identification, Study Status, Study Description v2
Study description+446 characters
The University of Minnesota holds equity in, and has rights to potential royalties from, Myogenica, the company that has licensed this trial's stem cell therapy from the University. These interests have been reviewed and managed by the University of Minnesota in accordance with its conflict of inter [...]
Study title-5 characters
Ph I Trial of Cell Based Therapy for DMD
2025-01-15
Study Status, Study Design v1
Start date2024-12-16→2025-05-16
2024-11-14
Original filing
This is a single-center, single-arm, interventional phase 1 trial to evaluate the safety and tolerability of local injection of induced pluripotent stem cell (iPSC)- derived CD54+ allogeneic muscle progenitor cells in individuals with Duchenne muscular dystrophy (DMD)
Trial Details
NCT Number NCT06692426
Lead Sponsor Masonic Cancer Center, University of Minnesota
Collaborators: Duchenne UK, Parent Project Muscular Dystrophy
Conditions Duchenne Muscular Dystrophy
Enrollment 8 participants
Start Date 2025-03-20
Primary Completion 2027-03-03 (estimated)
Study Completion 2027-03-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-04